Dimers of 5HT1 ligands preferentially bind to 5HT(1B/1D) receptor subtypes

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 11, 1998, Pages 1407-1412

  Perez, Michel ^a   Jorand Lebrun, Catherine ^a   Pauwels, Petrus J ^b   Pallard, Isabelle ^a   Halazy, Serge ^a  

^a Division of Medicinal Chemistry   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHYLPIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DIMER; RECEPTOR SUBTYPE; SEROTONIN 1 AGONIST; SEROTONIN 1B RECEPTOR; UNCLASSIFIED DRUG; 1 (1 NAPHTHYL)PIPERAZINE; 1-(1-NAPHTHYL)PIPERAZINE; CYCLIC AMP; DRUG DERIVATIVE; HTR1B PROTEIN, HUMAN; LIGAND; PIPERAZINE DERIVATIVE; RECOMBINANT PROTEIN; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; BINDING AFFINITY; DIMERIZATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR CLONING; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; STRUCTURE ANALYSIS; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; RADIOASSAY; SYNTHESIS;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; CYCLIC AMP; HUMANS; LIGANDS; PIPERAZINES; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RECOMBINANT PROTEINS; SEROTONIN; SEROTONIN AGENTS; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0032474283     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00222-4     Document Type: Article

References (21)

1. 1) Glennon, R. A.; Dukat, M. Serotonin ID Research Alert 1997, 2, 351-372.
2. 2) Hartig, P. R.; Hoyer, D.; Humphrey, P. P. A.; Martin, G. R. Trends Pharmacol. Sci. 1996, 17, 103-105.
3. 3) Saudou, F.; Hen, R. Med. Chem. Res. 1994, 4, 16-84.
4. 4) Peroutka, S. J. Biol. Signals 1994, 3, 217-222.
5. 5) Pauwels, P. J.; Palmier, C.; Wurch, T.; Colpaert, F. C. Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 353, 144-156.
6. 6) Hamel, E. Research Alerts Serotonin 1996, 1, 19-29.
7. 7) Fink, K.; Zentner, J.; Göthert, M. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 352, 451-454.
8. 8) Branchek, T.; Audia, J. E. Annual reports in medicinal chemistry 1997, 32, 1-10.
9. 9) Halazy, S.; Lamothe, M.; Jorand-Lebrun, C. Exp. Opin. Ther. Pat. 1997, 7, 339-352.
10. 10) Portoghese, P. S. Trends Pharmacol. Sci. 1989, 10, 230-235.
11. 11) Portoghese, P. S. J. Med. Chem. 1992, 35, 1927-1937.
12. 12) Halazy, S.; Perez, M.; Fourrier, C.; Pallard, I.; Pauwels, P. J.; Palmier, C.; John, G. W.; Valentin, J.-P.; Bonnafous, R.; Martinez, J. J. Med. Chem. 1996, 39, 4920-4927.
13. 13) Glennon, R. A.; Ismaiel, A. M.; Chaurasia, C.; Titeler, M. Drug Dev. Res. 1991, 22, 25-36.
14. 14) All new compounds have been fully characterized by CHN analysis, IR, MS and NMR spectra.
15. 15) Jorand-Lebrun, C.; Pauwels, P. J.; Palmier, C.; Moret, C.; Chopin, P.; Perez, M.; Marien, M.; Halazy, S. J. Med. Chem. 1997, 40, 3974-3978.
16. 16) Perez, M.; Pauwels, P. J.; Palmier, C.; John, G. W.; Valentin, J.-P.; Halazy, S. Med. Chem. Res. 1995, 5, 680-689.
17. 17) Perez, M.; Ayerbe, N.; Fourrier, C.; Sigogneau, I.; Pauwels, P. J.; Palmier, C.; John, G. W.; Valentin, J.-P.; Halazy, S. Eur. J. Med. Chem. 1997, 32, 129-134.
18. 18) Pauwels, P. J.; Van Gompel, P.; Leysen, J. E. Biochem. Pharmacol. 1993, 45, 375-383.
19. 19) Pauwels, P. J.; Palmier, C.; Colpaert, F. C. Cell. Pharmacol. 1995, 2, 49-57.
20. 20) Moret, C.; Briley, M. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 351, 377-384.
21. 21) Samama, P.; Cotecchia, S.; Costa, T.; Lefkowitz, R. J. J. Biol. Chem. 1993, 268, 4625-4636.